Results of Operations and Financial Condition. On July 30, 2026, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that…

The excerpt is incomplete and does not provide sufficient details to determine the nature of the event.

Results of Operations and Financial Condition. On May 5, 2026, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that s…

Chief Development and Technology Officer — Dr. Kevin Haas: The company appointed Dr. Kevin Haas as Chief Development and Technology Officer.

Results of Operations and Financial Condition. On February 25, 2026, Veracyte, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the l…

Results of Operations and Financial Condition. On January 11, 2026, Veracyte, Inc. a Delaware corporation (“Veracyte”), issued a press release furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Press Release”) that, among other things, announced certain preliminary, unaudited estimated financial and operating results for the fourth quarter and full year ended December 31, 2025, including that Veracyte expects to report that it generated total revenue of between $138 million an…

Results of Operations and Financial Condition. On November 4, 2025, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability…

Results of Operations and Financial Condition. On August 6, 2025, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that…

The provided text is only the standard Item 5.02 header and does not contain specific details about a person, role, or action to classify.

Results of Operations and Financial Condition. On May 7, 2025, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that s…

Results of Operations and Financial Condition. On February 24, 2025, Veracyte, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the l…

Results of Operations and Financial Condition. On November 6, 2024, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability…

Director — Tom Miller, Ph.D., and Brent Shafer: The filing discloses the appointment of two new directors to the board, which is a routine governance event and not a departure of a senior executive.

Results of Operations and Financial Condition. On August 6, 2024, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that…

The provided text is only the standard Item 5.02 header and does not contain the specific details of the event required to classify the movement.

Results of Operations and Financial Condition. On May 7, 2024, Veracyte, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. The full text of the press release is furnished as Exhibit 99.1 to this report. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liability of that s…

Other Events. On March 22, 2024, Veracyte, Inc. (the “Company”) filed a prospectus supplement (“Prospectus Supplement”) to its effective shelf registration statement on Form S-3ASR (File No. 333-277529) filed with the Securities and Exchange Commission on February 29, 2024. The Company filed the Prospectus Supplement for the purpose of registering for resale up to 1,016,965 shares of the Company’s common stock issued in connection with the Company’s acquisition of C2i Genomics, Inc., a Delawa…